1. Davidoff AM, Herndon JE II, Glover NS, et al. Relation between
p53 overexpression and established prognostic factors in breast cancer.
Surgery. 1991;110:259-264.
2. Thor AD, Moore DH II, Edgerton SM, et al. Accumulation of
p53 tumor suppressor gene protein: an independent marker of prognosis
in breast cancers. J Natl Cancer Inst. 1992;84:845-855.
3. Rosanelli GP, Steindorfer P, Wirnsberger GH, et al. Mutant
p53 expression and DNA analysis in human breast cancer comparison with
conventional clinicopathological parameters. Anticancer Res. 1995;15:
581-586.
4. Borg A, Lennerstrand J, Stenmark-Askmalm M, et al. Prognostic
significance of p53 overexpression in primary breast cancer; a novel
luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer.
1995;71:1013-1017.
5. Tsuda H, Hirohashi S. Association among p53 gene
mutation, nuclear accumulation of the p53 protein and aggressive phenotypes
in breast cancer. Int J Cancer. 1994;57:498-503.
6. Faille A, De Cremoux P, Extra JM, et al. p53 mutations
and overexpression in locally advanced breast cancers. Br J Cancer. 1994;69:1145-1150.
7. Isola J, Visakorpi T, Holli K, et al. Association of overexpression
of tumor suppressor protein p53 with rapid cell proliferation and poor
prognosis in node-negative breast cancer patients. J Natl Cancer Inst.
1992;84:1109-1114.
8. Molina R, Segui MA, Climent MA, et al. p53 oncoprotein
as a prognostic indicator in patients with breast cancer. Anticancer Res.
1998;18:507-511.
9. Falette N, Paperin MP, Treilleux I, et al. Prognostic value
of p53 gene mutations in a large series of node-negative breast cancer
patients. Cancer Res. 1998;58:1451-1455.
10. Martinazzi M, Crivelli F, Zampatti C, et al. Relationship
between p53 expression and other prognostic factors in human breast carcinoma.
An immunohistochemical study. Am J Clin Pathol. 1993;100:213-217.
11. Marchetti A, Buttitta F, Pellegrini S, et al. p53
mutations and histological type of invasive breast carcinoma. Cancer Res.
1993;53:4665-4669.
12. Gee JM, Robertson JF, Ellis IO, et al. Immunocytochemical
localization of Bcl-2 protein in human breast cancers and its relationship
to a series of prognostic markers and response to endocrine therapy. Int
J Cancer. 1994;59:619-628.
13. Nathan B, Gusterson B, Jadayel D, et al. Expression of
Bcl-2 in primary breast cancer and its correlation with tumor phenotype.
Ann Oncol. 1994;5:409-414.
14. Bargou RC, Daniel PT, Mapara MY, et al. Expression of the
bcl-2 gene family in normal and malignant breast tissue: low bax-alpha
expression in tumor cells correlates with resistance towards apoptosis. Int
J Cancer. 1995;60:854-859.
15. Leek RD, Kaklamanis L, Pezzella F, et al. Bcl-2
in normal human breast and carcinoma, association with oestrogen receptor-positive,
epidermal growth factor receptor-negative tumors and in situ cancer. Br J
Cancer. 1994;69:135-139.
16. Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2
protein: a prognostic indicator strongly related to p53 protein in lymph
node-negative breast cancer patients. J Natl Cancer Inst. 1994;86:499-504.
17. Haldar S, Negrini M, Monne M, et al. Down-regulation of
Bcl-2 by p53 in breast cancer cells. Cancer Res. 1994;54:2095-2097.
18. Kastan MB, Onyekwere O, Sidransky D, et al. Participation
of p53 protein in the cellular response to DNA damage. Cancer Res.
1991;51:6304-6311.
19. Zambetti GP, Bargonetti J, Walker K, et al. Wild-type p53
mediates positive regulation of gene expression through a specific DNA sequence
element. Genes Dev. 1992;6:1143-1152.
20. Kern SE, Pietenpol JA, Thiagalingam S, et al. Oncogenic
forms of p53 inhibit p53-regulated gene expression. Science.
1992; 256:827-830.
21. Fields S, Jang SK. Presence of a potent transcription activating
sequence in the p53 protein. Science. 1990;249:1046-1049.
22. Thorlacius S, Jonasdottir O, Eyfjord JE. Loss of heterozygosity
at selective sites on chromosomes 13 and 17 in human breast carcinoma. Anticancer
Res. 1991;11:1501-1507.
23. Varley JM, Brammar WJ, Lane DP, et al. Loss of chromosome
17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene.
1991;6:413-421.
24. Andersen TI, Holm R, Nesland JM, et al. Prognostic significance
of TP53 alterations in breast carcinomas. Br J Cancer. 1993;68:540-548.
25. Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel
density, p53 expression, tumor size, and peritumoral lymphatic vessel
invasion are relevant prognostic markers in node-negative breast carcinoma.
J Clin Oncol. 1994;12:454-466.
26. Berns EM, van Staveren IL, Look MP, et al. Mutations in
residues of TP53 that directly contact DNA predict poor outcome in human primary
breast cancer. Br J Cancer. 1998;77:1130-1136.
27. Bosari S, Lee AK, Viale G, et al. Abnormal p53 immunoreactivity
and prognosis in node-negative breast carcinomas with long-term follow-up. Virchow
Arch A Pathol Anat Histopathol. 1992;421:291-295.
28. Walker RA, Dearing SJ, Lane DP, et al. Expression of p53
protein in infiltrating and in situ breast carcinomas. J Pathol. 1991;165:203-211.
29. Yonish-Rouach E, Resnitzky D, Lotem J, et al. Wild-type
p53 induces apoptosis of myeloid leukaemic cells that is inhibited by
interleukin-6. Nature. 1991;352: 345-347.
30. Shaw P, Bovey R, Tardy S, et al. Induction of apoptosis
by wild-type p53 in a human colon tumor-derived cell line. Proc Natl
Acad Sci U S A. 1992;89:4495-4499.
31. Vaux DL, Cory S, Adams JM. bcl-2 gene promotes haemopoietic
cell survival and cooperates with c-myc to immortalize pre-B cells. Nature.
1988;335:440-442.
32. Hockenbery D, Nunez G, Milliman C, et al. Bcl-2
is an inner mitochondrial membrane protein that blocks programmed cell death.
Nature. 1990;348:334-336.
33. Nunez G, London L, Hockenbery D, et al. Deregulated bcl-2
gene expression selectively prolongs survival of growth factor-deprived hemopoietic
cell lines. J Immunol. 1990;144:3602-3610.
34. Bukholm IK, Nesland JM, Karesen R, et al. Interaction between
Bcl-2 and p21 (WAF1/CIP1) in breast carcinomas with wild-type p53.
Int J Cancer. 1997;73:38-41.
35. Poller DN, Hutchings CE, Galea M, et al. p53 protein
expression in human breast carcinoma: relationship to expression of epidermal
growth factor receptor, c-erbB2 protein over-expression, and oestrogen receptor.
Br J Cancer. 1992;66:583-588.
36. Poller DN, Roberts EC, Bell JA, et al. p53 protein
expression in mammary ductal carcinoma in situ: relationship to immunohistochemical
expression of estrogen receptor and c-erbB2 protein. Hum Pathol. 1993;24:463-468.
37. Ferrieres G, Cuny M, Simony-Lafontaine J, et al. Variation
of Bcl-2 expression in breast ducts and lobules in relation to plasma
progesterone levels: overexpression and absence of variation in fibroadenomas.
J Pathol. 1997;183:204-211.